Global Human Papillomavirus Vaccine (Types 16, 18) Market Growth 2022-2028

The global market for Human Papillomavirus Vaccine (Types 16, 18) is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Human Papillomavirus Vaccine (Types 16, 18) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Human Papillomavirus Vaccine (Types 16, 18) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Human Papillomavirus Vaccine (Types 16, 18) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Human Papillomavirus Vaccine (Types 16, 18) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Human Papillomavirus Vaccine (Types 16, 18) players cover GlaxoSmithKline, Merck & Co., Inc., Serum Institute of India, INNOVAX and ZSSW, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Human Papillomavirus Vaccine (Types 16, 18) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Human Papillomavirus Vaccine (Types 16, 18) market, with both quantitative and qualitative data, to help readers understand how the Human Papillomavirus Vaccine (Types 16, 18) market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the Human Papillomavirus Vaccine (Types 16, 18) market and forecasts the market size by Type (HPV16 and HPV18,), by Application (9-26 Years Old and 26-45 Years Old.), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
    HPV16
    HPV18

Segmentation by application
    9-26 Years Old
    26-45 Years Old

Segmentation by region
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

Major companies covered
    GlaxoSmithKline
    Merck & Co., Inc.
    Serum Institute of India
    INNOVAX
    ZSSW
    HUMANWELL HEALTHCARE
    WALVAX

Chapter Introduction
Chapter 1: Scope of Human Papillomavirus Vaccine (Types 16, 18), Research Methodology, etc.
Chapter 2: Executive Summary, global Human Papillomavirus Vaccine (Types 16, 18) market size (sales and revenue) and CAGR, Human Papillomavirus Vaccine (Types 16, 18) market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Human Papillomavirus Vaccine (Types 16, 18) sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Human Papillomavirus Vaccine (Types 16, 18) sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Human Papillomavirus Vaccine (Types 16, 18) market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including GlaxoSmithKline, Merck & Co., Inc., Serum Institute of India, INNOVAX, ZSSW, HUMANWELL HEALTHCARE and WALVAX, etc.
Chapter 14: Research Findings and Conclusion

List of Tables
    Table 1. Human Papillomavirus Vaccine (Types 16, 18) Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
    Table 2. Human Papillomavirus Vaccine (Types 16, 18) Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
    Table 3. Major Players of HPV16
    Table 4. Major Players of HPV18
    Table 5. Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2017-2022) & (K Units)
    Table 6. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2017-2022)
    Table 7. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Type (2017-2022) & ($ million)
    Table 8. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Type (2017-2022)
    Table 9. Global Human Papillomavirus Vaccine (Types 16, 18) Sale Price by Type (2017-2022) & (US$/Unit)
    Table 10. Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2017-2022) & (K Units)
    Table 11. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2017-2022)
    Table 12. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Application (2017-2022)
    Table 13. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Application (2017-2022)
    Table 14. Global Human Papillomavirus Vaccine (Types 16, 18) Sale Price by Application (2017-2022) & (US$/Unit)
    Table 15. Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Company (2020-2022) & (K Units)
    Table 16. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Company (2020-2022)
    Table 17. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Company (2020-2022) ($ Millions)
    Table 18. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Company (2020-2022)
    Table 19. Global Human Papillomavirus Vaccine (Types 16, 18) Sale Price by Company (2020-2022) & (US$/Unit)
    Table 20. Key Manufacturers Human Papillomavirus Vaccine (Types 16, 18) Producing Area Distribution and Sales Area
    Table 21. Players Human Papillomavirus Vaccine (Types 16, 18) Products Offered
    Table 22. Human Papillomavirus Vaccine (Types 16, 18) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    Table 23. New Products and Potential Entrants
    Table 24. Mergers & Acquisitions, Expansion
    Table 25. Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Geographic Region (2017-2022) & (K Units)
    Table 26. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share Geographic Region (2017-2022)
    Table 27. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Geographic Region (2017-2022) & ($ millions)
    Table 28. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Geographic Region (2017-2022)
    Table 29. Global Human Papillomavirus Vaccine (Types 16, 18) Sales by Country/Region (2017-2022) & (K Units)
    Table 30. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country/Region (2017-2022)
    Table 31. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country/Region (2017-2022) & ($ millions)
    Table 32. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country/Region (2017-2022)
    Table 33. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2017-2022) & (K Units)
    Table 34. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country (2017-2022)
    Table 35. Americas Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2017-2022) & ($ Millions)
    Table 36. Americas Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country (2017-2022)
    Table 37. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2017-2022) & (K Units)
    Table 38. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2017-2022)
    Table 39. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2017-2022) & (K Units)
    Table 40. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2017-2022)
    Table 41. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales by Region (2017-2022) & (K Units)
    Table 42. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Region (2017-2022)
    Table 43. APAC Human Papillomavirus Vaccine (Types 16, 18) Revenue by Region (2017-2022) & ($ Millions)
    Table 44. APAC Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Region (2017-2022)
    Table 45. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2017-2022) & (K Units)
    Table 46. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2017-2022)
    Table 47. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2017-2022) & (K Units)
    Table 48. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2017-2022)
    Table 49. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2017-2022) & (K Units)
    Table 50. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country (2017-2022)
    Table 51. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2017-2022) & ($ Millions)
    Table 52. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country (2017-2022)
    Table 53. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2017-2022) & (K Units)
    Table 54. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2017-2022)
    Table 55. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2017-2022) & (K Units)
    Table 56. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2017-2022)
    Table 57. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales by Country (2017-2022) & (K Units)
    Table 58. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country (2017-2022)
    Table 59. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue by Country (2017-2022) & ($ Millions)
    Table 60. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country (2017-2022)
    Table 61. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales by Type (2017-2022) & (K Units)
    Table 62. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type (2017-2022)
    Table 63. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales by Application (2017-2022) & (K Units)
    Table 64. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2017-2022)
    Table 65. Key Market Drivers & Growth Opportunities of Human Papillomavirus Vaccine (Types 16, 18)
    Table 66. Key Market Challenges & Risks of Human Papillomavirus Vaccine (Types 16, 18)
    Table 67. Key Industry Trends of Human Papillomavirus Vaccine (Types 16, 18)
    Table 68. Human Papillomavirus Vaccine (Types 16, 18) Raw Material
    Table 69. Key Suppliers of Raw Materials
    Table 70. Human Papillomavirus Vaccine (Types 16, 18) Distributors List
    Table 71. Human Papillomavirus Vaccine (Types 16, 18) Customer List
    Table 72. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Forecast by Region (2023-2028) & (K Units)
    Table 73. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Forecast by Region
    Table 74. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 75. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share Forecast by Region (2023-2028)
    Table 76. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales Forecast by Country (2023-2028) & (K Units)
    Table 77. Americas Human Papillomavirus Vaccine (Types 16, 18) Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 78. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales Forecast by Region (2023-2028) & (K Units)
    Table 79. APAC Human Papillomavirus Vaccine (Types 16, 18) Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 80. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales Forecast by Country (2023-2028) & (K Units)
    Table 81. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 82. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales Forecast by Country (2023-2028) & (K Units)
    Table 83. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 84. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Forecast by Type (2023-2028) & (K Units)
    Table 85. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share Forecast by Type (2023-2028)
    Table 86. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Forecast by Type (2023-2028) & ($ Millions)
    Table 87. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share Forecast by Type (2023-2028)
    Table 88. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Forecast by Application (2023-2028) & (K Units)
    Table 89. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share Forecast by Application (2023-2028)
    Table 90. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Forecast by Application (2023-2028) & ($ Millions)
    Table 91. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share Forecast by Application (2023-2028)
    Table 92. GlaxoSmithKline Basic Information, Human Papillomavirus Vaccine (Types 16, 18) Manufacturing Base, Sales Area and Its Competitors
    Table 93. GlaxoSmithKline Human Papillomavirus Vaccine (Types 16, 18) Product Offered
    Table 94. GlaxoSmithKline Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 95. GlaxoSmithKline Main Business
    Table 96. GlaxoSmithKline Latest Developments
    Table 97. Merck & Co., Inc. Basic Information, Human Papillomavirus Vaccine (Types 16, 18) Manufacturing Base, Sales Area and Its Competitors
    Table 98. Merck & Co., Inc. Human Papillomavirus Vaccine (Types 16, 18) Product Offered
    Table 99. Merck & Co., Inc. Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 100. Merck & Co., Inc. Main Business
    Table 101. Merck & Co., Inc. Latest Developments
    Table 102. Serum Institute of India Basic Information, Human Papillomavirus Vaccine (Types 16, 18) Manufacturing Base, Sales Area and Its Competitors
    Table 103. Serum Institute of India Human Papillomavirus Vaccine (Types 16, 18) Product Offered
    Table 104. Serum Institute of India Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 105. Serum Institute of India Main Business
    Table 106. Serum Institute of India Latest Developments
    Table 107. INNOVAX Basic Information, Human Papillomavirus Vaccine (Types 16, 18) Manufacturing Base, Sales Area and Its Competitors
    Table 108. INNOVAX Human Papillomavirus Vaccine (Types 16, 18) Product Offered
    Table 109. INNOVAX Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 110. INNOVAX Main Business
    Table 111. INNOVAX Latest Developments
    Table 112. ZSSW Basic Information, Human Papillomavirus Vaccine (Types 16, 18) Manufacturing Base, Sales Area and Its Competitors
    Table 113. ZSSW Human Papillomavirus Vaccine (Types 16, 18) Product Offered
    Table 114. ZSSW Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 115. ZSSW Main Business
    Table 116. ZSSW Latest Developments
    Table 117. HUMANWELL HEALTHCARE Basic Information, Human Papillomavirus Vaccine (Types 16, 18) Manufacturing Base, Sales Area and Its Competitors
    Table 118. HUMANWELL HEALTHCARE Human Papillomavirus Vaccine (Types 16, 18) Product Offered
    Table 119. HUMANWELL HEALTHCARE Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 120. HUMANWELL HEALTHCARE Main Business
    Table 121. HUMANWELL HEALTHCARE Latest Developments
    Table 122. WALVAX Basic Information, Human Papillomavirus Vaccine (Types 16, 18) Manufacturing Base, Sales Area and Its Competitors
    Table 123. WALVAX Human Papillomavirus Vaccine (Types 16, 18) Product Offered
    Table 124. WALVAX Human Papillomavirus Vaccine (Types 16, 18) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 125. WALVAX Main Business
    Table 126. WALVAX Latest Developments
List of Figures
    Figure 1. Picture of Human Papillomavirus Vaccine (Types 16, 18)
    Figure 2. Human Papillomavirus Vaccine (Types 16, 18) Report Years Considered
    Figure 3. Research Objectives
    Figure 4. Research Methodology
    Figure 5. Research Process and Data Source
    Figure 6. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Growth Rate 2017-2028 (K Units)
    Figure 7. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth Rate 2017-2028 ($ Millions)
    Figure 8. Human Papillomavirus Vaccine (Types 16, 18) Sales by Region (2021 & 2028) & ($ millions)
    Figure 9. Product Picture of HPV16
    Figure 10. Product Picture of HPV18
    Figure 11. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Type in 2021
    Figure 12. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Type (2017-2022)
    Figure 13. Human Papillomavirus Vaccine (Types 16, 18) Consumed in 9-26 Years Old
    Figure 14. Global Human Papillomavirus Vaccine (Types 16, 18) Market: 9-26 Years Old (2017-2022) & (K Units)
    Figure 15. Human Papillomavirus Vaccine (Types 16, 18) Consumed in 26-45 Years Old
    Figure 16. Global Human Papillomavirus Vaccine (Types 16, 18) Market: 26-45 Years Old (2017-2022) & (K Units)
    Figure 17. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Application (2017-2022)
    Figure 18. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Application in 2021
    Figure 19. Human Papillomavirus Vaccine (Types 16, 18) Revenue Market by Company in 2021 ($ Million)
    Figure 20. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Company in 2021
    Figure 21. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Geographic Region (2017-2022)
    Figure 22. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Geographic Region in 2021
    Figure 23. Global Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Region (2017-2022)
    Figure 24. Global Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country/Region in 2021
    Figure 25. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales 2017-2022 (K Units)
    Figure 26. Americas Human Papillomavirus Vaccine (Types 16, 18) Revenue 2017-2022 ($ Millions)
    Figure 27. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales 2017-2022 (K Units)
    Figure 28. APAC Human Papillomavirus Vaccine (Types 16, 18) Revenue 2017-2022 ($ Millions)
    Figure 29. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales 2017-2022 (K Units)
    Figure 30. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue 2017-2022 ($ Millions)
    Figure 31. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales 2017-2022 (K Units)
    Figure 32. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue 2017-2022 ($ Millions)
    Figure 33. Americas Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country in 2021
    Figure 34. Americas Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country in 2021
    Figure 35. United States Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 36. Canada Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 37. Mexico Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 38. Brazil Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 39. APAC Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Region in 2021
    Figure 40. APAC Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Regions in 2021
    Figure 41. China Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 42. Japan Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 43. South Korea Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 44. Southeast Asia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 45. India Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 46. Australia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 47. Europe Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country in 2021
    Figure 48. Europe Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country in 2021
    Figure 49. Germany Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 50. France Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 51. UK Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 52. Italy Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 53. Russia Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 54. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Sales Market Share by Country in 2021
    Figure 55. Middle East & Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue Market Share by Country in 2021
    Figure 56. Egypt Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 57. South Africa Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 58. Israel Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 59. Turkey Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 60. GCC Country Human Papillomavirus Vaccine (Types 16, 18) Revenue Growth 2017-2022 ($ Millions)
    Figure 61. Manufacturing Cost Structure Analysis of Human Papillomavirus Vaccine (Types 16, 18) in 2021
    Figure 62. Manufacturing Process Analysis of Human Papillomavirus Vaccine (Types 16, 18)
    Figure 63. Industry Chain Structure of Human Papillomavirus Vaccine (Types 16, 18)
    Figure 64. Channels of Distribution
    Figure 65. Distributors Profiles

This latest report provides a deep insight into the global Human Papillomavirus Vaccine (Types 16, 18) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Human Papillomavirus Vaccine (Types 16, 18) market, with both quantitative and qualitative data, to help readers understand how the Human Papillomavirus Vaccine (Types 16, 18) market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Human Papillomavirus Vaccine (Types 16, 18) market and forecasts the market size by Type (HPV16 and HPV18,), by Application (9-26 Years Old and 26-45 Years Old.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
    HPV16
    HPV18
Segmentation by application
    9-26 Years Old
    26-45 Years Old
Segmentation by region
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries
Major companies covered
    GlaxoSmithKline
    Merck & Co., Inc.
    Serum Institute of India
    INNOVAX
    ZSSW
    HUMANWELL HEALTHCARE
    WALVAX
Chapter Introduction
Chapter 1: Scope of Human Papillomavirus Vaccine (Types 16, 18), Research Methodology, etc.
Chapter 2: Executive Summary, global Human Papillomavirus Vaccine (Types 16, 18) market size (sales and revenue) and CAGR, Human Papillomavirus Vaccine (Types 16, 18) market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Human Papillomavirus Vaccine (Types 16, 18) sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Human Papillomavirus Vaccine (Types 16, 18) sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Human Papillomavirus Vaccine (Types 16, 18) market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including GlaxoSmithKline, Merck & Co., Inc., Serum Institute of India, INNOVAX, ZSSW, HUMANWELL HEALTHCARE and WALVAX, etc.
Chapter 14: Research Findings and Conclusion

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

• Primary Source
  Players/Suppliers
  Industry Experts
  Distributors/Traders
  Opinion Leaders
  Front-line Staff
  Marketing Executives

  Secondary Source
  Journals and Periodicals
  Government Bodies
  Annual Reports
  Presentations
  Paid Databases
  LPI Internal Repository

• Data Synthesis
  Information Gathering
  Collation of Data
  Estimation of Key Figures
  Analysis of Derived Insights

  Data Validation
  Triangulation with Data Models
  Reference Against Proprietary
  Databases
  Corroboration with Industry Experts

• Qualitative Analysis
  Market drivers
  Market challenges
  Market trends
  Five forces analysis

  Qualitative Analysis
  Market size and forecast
  Market segmentation
  Geographical insights
  Competitive landscape